Circulating Omentin-1 Levels Are Decreased in Dilated Cardiomyopathy Patients with Overt Heart Failure

Disease Markers

Volumn 2016, Issue , 2016, Pages

  Huang, Ying ^a   Lin, Yingzhong ^a   Zhang, Shumin ^b   Wang, Zhijian ^c   Zhang, Jianwei ^c   Chang, Chao ^c   Liu, Ling ^a   Ji, Qingwei ^a   Liu, Xiaofei ^d  

^a PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^b Departmet of General Surgery   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATINE KINASE MB; CREATININE; GLUCOSE; LIPOPROTEIN; OMENTIN 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR PARAMETERS; COMPARATIVE STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; GOLD STANDARD; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; LEFT VENTRICULAR END DIASTOLIC DIAMETER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CARDIOMYOPATHY, DILATED; CASE CONTROL STUDY; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; PROGNOSIS;

BIOMARKERS; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GPI-LINKED PROTEINS; HEART FAILURE; HUMANS; LECTINS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 84975070392     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2016/6762825     Document Type: Article

References (30)

1. D. Cihakova and N. R. Rose, "Pathogenesis of myocarditis and dilated cardiomyopathy, " Advances in Immunology, vol. 99, pp. 95-114, 2008.
2. N. R. Rose, "Critical cytokine pathways to cardiac inflammation, " Journal of Interferon and Cytokine Research, vol. 31, no. 10, pp. 705-710, 2011.
3. S. Pankuweit, V. Ruppert, and B. Maisch, "Inflammation in dilated cardiomyopathy, " Herz, vol. 29, no. 8, pp. 788-793, 2004.
4. A. Deswal, N. J. Petersen, A. M. Feldman, J. B. Young, B. G. White, and D. L. Mann, "Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST), " Circulation, vol. 103, no. 16, pp. 2055-2059, 2001.
5. A. A. El-Menyar, "Cytokines and myocardial dysfunction: state of the art, " Journal of Cardiac Failure, vol. 14, no. 1, pp. 61-74, 2008.
6. E. S. Chung, M. Packer, K. H. Lo, A. A. Fasanmade, and J. T. Willerson, "Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial, " Circulation, vol. 107, no. 25, pp. 3133-3140, 2003.
7. K. Node, M. Fujita, M. Kitakaze, M. Hori, and J. K. Liao, "Shortterm statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy, " Circulation, vol. 108, no. 7, pp. 839-843, 2003.
8. S. Deftereos, G. Giannopoulos, V. Panagopoulou et al., "Antiinflammatory treatment with colchicine in stable chronic heart failure: A prospective, randomized study, " JACC: Heart Failure, vol. 2, no. 2, pp. 131-137, 2014.
9. J. Y. Huh, Y. J. Park, M. Ham, and J. B. Kim, "Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity, " Molecules and Cells, vol. 37, no. 5, pp. 365-371, 2014.
10. S. Hefetz-Sela and P. E. Scherer, "Adipocytes: impact on tumor growth and potential sites for therapeutic intervention, " Pharmacology andTherapeutics, vol. 138, no. 2, pp. 197-210, 2013.
11. C. Kistorp, J. Faber, S. Galatius et al., "Plasma adiponectin, body mass index, andmortality in patients with chronic heart failure, " Circulation, vol. 112, no. 12, pp. 1756-1762, 2005.
12. J. George, S. Patal, D. Wexler et al., "Circulating adiponectin concentrations in patients with congestive heart failure, " Heart, vol. 92, no. 10, pp. 1420-1424, 2006.
13. J. Paulo Araújo, P. Lourenço, F. Rocha-Gonçalves, A. Ferreira, and P. Bettencourt, "Adiponectin is increased in cardiac cachexia irrespective of body mass index, " European Journal of Heart Failure, vol. 11, no. 6, pp. 567-572, 2009.
14. P. C. Schulze, A. Biolo, D. Gopal et al., "Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure, " Journal of Cardiac Failure, vol. 17, no. 12, pp. 1004-1011, 2011.
15. P. C. Schulze, J. Kratzsch, A. Linke et al., "Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure, " European Journal of Heart Failure, vol. 5, no. 1, pp. 33-40, 2003.
16. C. Jaikanth, P. Gurumurthy, K. M. Cherian, and T. Indhumathi, "Emergence of omentin as a pleiotropic adipocytokine, " Experimental and Clinical Endocrinology and Diabetes, vol. 121, no. 7, pp. 377-383, 2013.
17. J.-Y. Zhou, L. Chan, and S.-W. Zhou, "Omentin: linking metabolic syndrome and cardiovascular disease, " Current Vascular Pharmacology, vol. 12, no. 1, pp. 136-143, 2014.
18. A. Schäffler, M. Neumeier, H. Herfarth, A. Fürst, J. Schölmerich, and C. Büchler, "Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue, " Biochimica et BiophysicaActa-Gene Structure and Expression, vol. 1732, no. 1-3, pp. 96-102, 2005.
19. R. Shibata, N. Ouchi, R. Kikuchi et al., "Circulating omentin is associated with coronary artery disease inmen, " Atherosclerosis, vol. 219, no. 2, pp. 811-814, 2011.
20. H. J. Yoo, S. Y. Hwang, H. C. Hong et al., "Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes, " Cardiovascular Diabetology, vol. 10, article 103, 2011.
21. G. Derosa, A. F. G. Cicero, A. Carbone et al., "Results from a 12 months, randomized, clinical trial comparing an olmesartan/ amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation, " European Journal of Pharmaceutical Sciences, vol. 51, no. 1, pp. 26-33, 2014.
22. X.-H. Wang, L.-Z. Dou, C. Gu, and X.-Q. Wang, "Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure, " Asian Pacific Journal of Tropical Medicine, vol. 7, no. 1, pp. 55-62, 2014.
23. T. Narumi, T. Watanabe, S. Kadowaki et al., "Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure, " Cardiovascular Diabetology, vol. 13, article 84, 2014.
24. S. Barth, P. Klein, T. Horbach et al., "Expression of neuropeptide Y, omentin and visfatin in visceral and subcutaneous adipose tissues in humans: relation to endocrine and clinical parameters, " Obesity Facts, vol. 3, no. 4, pp. 245-251, 2010.
25. L. Senolt, M. Polanská, M. Filková et al., "Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis, " Annals of the Rheumatic Diseases, vol. 69, no. 7, pp. 1410-1411, 2010.
26. O. Tsukamoto, M. Fujita, M. Kato et al., "Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure, " Journal of the American College of Cardiology, vol. 53, no. 22, pp. 2070-2077, 2009.
27. T. Tsutamoto, M. Yamaji, C. Kawahara et al., "Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure, " European Journal of Heart Failure, vol. 11, no. 12, pp. 1195-1201, 2009.
28. A. M. Van Berendoncks, P. Beckers, V. Y. Hoymans et al., "-blockers modify the prognostic value of adiponectin in chronic heart failure, " International Journal of Cardiology, vol. 150, no. 3, pp. 296-300, 2011.
29. D. Giannessi, C. Caselli, S. Del Ry et al., "Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure, " Metabolism: Clinical and Experimental, vol. 60, no. 2, pp. 227-233, 2011.
30. Y. Kataoka, R. Shibata, K. Ohashi et al., "Omentin prevents myocardial ischemic injury through AMP-activated protein kinase-and akt-dependent mechanisms, " Journal of the American College of Cardiology, vol. 63, no. 24, pp. 2722-2733, 2014.